PSTV

Plus Therapeuticsdistress 6/10 · elevated risk

$3.78-1%today-83% from 52w high

plustherapeutics.com28 employeesFounded 1996Houston, TXBiotechnology

Oncology 2

Lead: Glioma

Revenue

pre-revenue

Liquidity

$15M

Runway

0.7 yrs

Shares 1y

-93%

Price & events

-47.9% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.0%

-3.1%

-7.4%

-48.1%

-44.0%

-69.1%

-91.4%

-99.5%

All

Overview

Market Cap: $26.02M
Volume: 3.46K
52 Week Range: $2.92 – $22.25
Total Shares: 6.88M
Float Shares: 6.46M
Short %: 14.74%
% Held by Insiders: 1.84%
% Held by Institutions: 10.23%
RVOL: 0.02x
Beta: 1.40

Pipeline stages · 3 programs

186RNL

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-10-02

Rhenium-186 Nanoliposome

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-03

Retreatment Rhenium Liposome

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-03-01

Pipeline · 5 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-10-02 Estimated 50% readout ~2026-11-01	Phase 1	186RNL	Leptomeningeal Metastasis	—	recruiting
2027-03 Estimated 50% readout ~2027-03-31	Phase 1	Rhenium-186 Nanoliposome	Ependymoma, High Grade Gliomas	—	not yet recruiting
2028-03-01 Estimated 50% readout ~2028-03-31	Phase 1	Retreatment Rhenium Liposome	Glioma	—	recruiting
2025-12-21	Phase 1	186RNL	Leptomeningeal Metastasis	18	active not recruiting
2025-12	Phase 1/2	Rhenium Liposome Treatment	Glioma	55	recruiting